A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

Y. K. Kang, S. Y. Rha, P. Tassone, J. Barriuso, R. Yu, T. Szado, A. Garg, Y. J. Bang

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Background:Pertuzumab plus trastuzumab provides a more comprehensive blockade of HER2 signalling than trastuzumab alone. Therefore, we conducted a phase IIa study of the pharmacokinetics and safety of pertuzumab plus trastuzumab and chemotherapy in advanced gastric cancer (aGC). Methods:Patients received pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2-6 (Arm A) or pertuzumab 840 mg q3w for six cycles (Arm B). Trastuzumab, cisplatin and capecitabine were also given for six cycles, then trastuzumab q3w until disease progression or unmanageable toxicity. The co-primary endpoints were day 43 pertuzumab serum trough concentration (C min) and safety.Results:Thirty patients were randomised. Mean pertuzumab C min at day 43 was 40.0 μg ml-1 (s.d.: 17.3) in Arm A and 62.7 μg ml-1 (29.1) in Arm B. Mean day 43 C min in Arm A was ∼37% lower than that seen in metastatic breast cancer. The safety profiles were similar between arms and treatment was well tolerated. Partial responses were achieved by 86% and 55% of patients in Arms A and B, respectively.Conclusions:On the basis of the pharmacokinetic and safety data, the 840 mg q3w pertuzumab dose has been selected for a phase III study of pertuzumab, trastuzumab and chemotherapy in HER2-positive aGC.

Original languageEnglish
Pages (from-to)660-666
Number of pages7
JournalBritish journal of cancer
Volume111
Issue number4
DOIs
Publication statusPublished - 2014 Aug 12

Fingerprint

Cisplatin
Stomach Neoplasms
Safety
Pharmacokinetics
Drug Therapy
Capecitabine
Trastuzumab
pertuzumab
Disease Progression
Breast Neoplasms
Serum

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{0607d05b1f6546809802ad3de8c7af60,
title = "A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer",
abstract = "Background:Pertuzumab plus trastuzumab provides a more comprehensive blockade of HER2 signalling than trastuzumab alone. Therefore, we conducted a phase IIa study of the pharmacokinetics and safety of pertuzumab plus trastuzumab and chemotherapy in advanced gastric cancer (aGC). Methods:Patients received pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2-6 (Arm A) or pertuzumab 840 mg q3w for six cycles (Arm B). Trastuzumab, cisplatin and capecitabine were also given for six cycles, then trastuzumab q3w until disease progression or unmanageable toxicity. The co-primary endpoints were day 43 pertuzumab serum trough concentration (C min) and safety.Results:Thirty patients were randomised. Mean pertuzumab C min at day 43 was 40.0 μg ml-1 (s.d.: 17.3) in Arm A and 62.7 μg ml-1 (29.1) in Arm B. Mean day 43 C min in Arm A was ∼37{\%} lower than that seen in metastatic breast cancer. The safety profiles were similar between arms and treatment was well tolerated. Partial responses were achieved by 86{\%} and 55{\%} of patients in Arms A and B, respectively.Conclusions:On the basis of the pharmacokinetic and safety data, the 840 mg q3w pertuzumab dose has been selected for a phase III study of pertuzumab, trastuzumab and chemotherapy in HER2-positive aGC.",
author = "Kang, {Y. K.} and Rha, {S. Y.} and P. Tassone and J. Barriuso and R. Yu and T. Szado and A. Garg and Bang, {Y. J.}",
year = "2014",
month = "8",
day = "12",
doi = "10.1038/bjc.2014.356",
language = "English",
volume = "111",
pages = "660--666",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. / Kang, Y. K.; Rha, S. Y.; Tassone, P.; Barriuso, J.; Yu, R.; Szado, T.; Garg, A.; Bang, Y. J.

In: British journal of cancer, Vol. 111, No. 4, 12.08.2014, p. 660-666.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

AU - Kang, Y. K.

AU - Rha, S. Y.

AU - Tassone, P.

AU - Barriuso, J.

AU - Yu, R.

AU - Szado, T.

AU - Garg, A.

AU - Bang, Y. J.

PY - 2014/8/12

Y1 - 2014/8/12

N2 - Background:Pertuzumab plus trastuzumab provides a more comprehensive blockade of HER2 signalling than trastuzumab alone. Therefore, we conducted a phase IIa study of the pharmacokinetics and safety of pertuzumab plus trastuzumab and chemotherapy in advanced gastric cancer (aGC). Methods:Patients received pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2-6 (Arm A) or pertuzumab 840 mg q3w for six cycles (Arm B). Trastuzumab, cisplatin and capecitabine were also given for six cycles, then trastuzumab q3w until disease progression or unmanageable toxicity. The co-primary endpoints were day 43 pertuzumab serum trough concentration (C min) and safety.Results:Thirty patients were randomised. Mean pertuzumab C min at day 43 was 40.0 μg ml-1 (s.d.: 17.3) in Arm A and 62.7 μg ml-1 (29.1) in Arm B. Mean day 43 C min in Arm A was ∼37% lower than that seen in metastatic breast cancer. The safety profiles were similar between arms and treatment was well tolerated. Partial responses were achieved by 86% and 55% of patients in Arms A and B, respectively.Conclusions:On the basis of the pharmacokinetic and safety data, the 840 mg q3w pertuzumab dose has been selected for a phase III study of pertuzumab, trastuzumab and chemotherapy in HER2-positive aGC.

AB - Background:Pertuzumab plus trastuzumab provides a more comprehensive blockade of HER2 signalling than trastuzumab alone. Therefore, we conducted a phase IIa study of the pharmacokinetics and safety of pertuzumab plus trastuzumab and chemotherapy in advanced gastric cancer (aGC). Methods:Patients received pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2-6 (Arm A) or pertuzumab 840 mg q3w for six cycles (Arm B). Trastuzumab, cisplatin and capecitabine were also given for six cycles, then trastuzumab q3w until disease progression or unmanageable toxicity. The co-primary endpoints were day 43 pertuzumab serum trough concentration (C min) and safety.Results:Thirty patients were randomised. Mean pertuzumab C min at day 43 was 40.0 μg ml-1 (s.d.: 17.3) in Arm A and 62.7 μg ml-1 (29.1) in Arm B. Mean day 43 C min in Arm A was ∼37% lower than that seen in metastatic breast cancer. The safety profiles were similar between arms and treatment was well tolerated. Partial responses were achieved by 86% and 55% of patients in Arms A and B, respectively.Conclusions:On the basis of the pharmacokinetic and safety data, the 840 mg q3w pertuzumab dose has been selected for a phase III study of pertuzumab, trastuzumab and chemotherapy in HER2-positive aGC.

UR - http://www.scopus.com/inward/record.url?scp=84906092045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906092045&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.356

DO - 10.1038/bjc.2014.356

M3 - Article

C2 - 24960402

AN - SCOPUS:84906092045

VL - 111

SP - 660

EP - 666

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -